MAPT and Alzheimer disease: This suggests that future models could consider incorporating an AT(N)I framework, where inflammation (I) biomarkers like GFAP are integrated alongside amyloid, tau, and neurodegeneration markers to provide a more comprehensive understanding of disease progression and diagnosis in AD, particularly in high‐risk groups like DS.